Your browser doesn't support javascript.
Baricitinib reduces 30-day mortality in older adults with moderate-to-severe COVID-19 pneumonia.
Abizanda, Pedro; Calbo Mayo, Juan María; Mas Romero, Marta; Cortés Zamora, Elisa Belén; Tabernero Sahuquillo, María Teresa; Romero Rizos, Luis; Sánchez-Jurado, Pedro Manuel; Sánchez-Nievas, Ginés; Campayo Escolano, Carlos; Ochoa Serrano, Alba; Sánchez-Flor Alfaro, Victoria; López Bru, Rita; Gómez Ballesteros, Cristina; Caldevilla Bernardo, David; Callejas González, Francisco Javier; Andrés-Pretel, Fernando; Lauschke, Volker Martin; Stebbing, Justin.
  • Abizanda P; Department of Geriatrics, Complejo Hospitalario Universitario de Albacete, Albacete, Spain.
  • Calbo Mayo JM; CIBERFES, Ministerio de Economía y Competitividad, Madrid, Spain.
  • Mas Romero M; Facultad de Medicina, Universidad de Castilla-La Mancha, Albacete, Spain.
  • Cortés Zamora EB; Department of Internal Medicine, Complejo Hospitalario Universitario de Albacete, Albacete, Spain.
  • Tabernero Sahuquillo MT; Department of Geriatrics, Complejo Hospitalario Universitario de Albacete, Albacete, Spain.
  • Romero Rizos L; Department of Geriatrics, Complejo Hospitalario Universitario de Albacete, Albacete, Spain.
  • Sánchez-Jurado PM; CIBERFES, Ministerio de Economía y Competitividad, Madrid, Spain.
  • Sánchez-Nievas G; Department of Geriatrics, Complejo Hospitalario Universitario de Albacete, Albacete, Spain.
  • Campayo Escolano C; Department of Geriatrics, Complejo Hospitalario Universitario de Albacete, Albacete, Spain.
  • Ochoa Serrano A; CIBERFES, Ministerio de Economía y Competitividad, Madrid, Spain.
  • Sánchez-Flor Alfaro V; Facultad de Medicina, Universidad de Castilla-La Mancha, Albacete, Spain.
  • López Bru R; Department of Geriatrics, Complejo Hospitalario Universitario de Albacete, Albacete, Spain.
  • Gómez Ballesteros C; CIBERFES, Ministerio de Economía y Competitividad, Madrid, Spain.
  • Caldevilla Bernardo D; Facultad de Medicina, Universidad de Castilla-La Mancha, Albacete, Spain.
  • Callejas González FJ; Department of Rheumatology, Complejo Hospitalario Universitario de Albacete, Albacete, Spain.
  • Andrés-Pretel F; Department of Internal Medicine, Complejo Hospitalario Universitario de Albacete, Albacete, Spain.
  • Lauschke VM; Department of Internal Medicine, Complejo Hospitalario Universitario de Albacete, Albacete, Spain.
  • Stebbing J; Department of Geriatrics, Complejo Hospitalario Universitario de Albacete, Albacete, Spain.
J Am Geriatr Soc ; 69(10): 2752-2758, 2021 10.
Article in English | MEDLINE | ID: covidwho-1301522
ABSTRACT

BACKGROUND:

Older adults are at the highest risk of severe disease and death due to COVID-19. Randomized data have shown that baricitinib improves outcomes in these patients, but focused stratified analyses of geriatric cohorts are lacking. Our objective was to analyze the efficacy of baricitinib in older adults with COVID-19 moderate-to-severe pneumonia.

METHODS:

This is a propensity score [PS]-matched retrospective cohort study. Patients from the COVID-AGE and Alba-Score cohorts, hospitalized for moderate-to-severe COVID-19 pneumonia, were categorized in two age brackets of age <70 years old (86 with baricitinib and 86 PS-matched controls) or ≥70 years old (78 on baricitinib and 78 PS-matched controls). Thirty-day mortality rates were analyzed with Kaplan-Meier and Cox proportional hazard models.

RESULTS:

Mean age was 79.1 for those ≥70 years and 58.9 for those <70. Exactly 29.6% were female. Treatment with baricitinib resulted in a significant reduction in death from any cause by 48% in patients aged 70 or older, an 18.5% reduction in 30-day absolute mortality risk (n/N 16/78 [20.5%] baricitinib, 30/78 [38.5%] in PS-matched controls, p < 0.001) and a lower 30-day adjusted fatality rate (HR 0.21; 95% CI 0.09-0.47; p < 0.001). Beneficial effects on mortality were also observed in the age group <70 (8.1% reduction in 30-day absolute mortality risk; HR 0.14; 95% CI 0.03-0.64; p = 0.011).

CONCLUSIONS:

Baricitinib is associated with an absolute mortality risk reduction of 18.5% in adults older than 70 years hospitalized with COVID-19 pneumonia.
Subject(s)
Keywords

Full text: Available Collection: International databases Database: MEDLINE Main subject: Pneumonia, Viral / Purines / Pyrazoles / Sulfonamides / Azetidines / COVID-19 / COVID-19 Drug Treatment Type of study: Cohort study / Diagnostic study / Experimental Studies / Observational study / Prognostic study / Randomized controlled trials Limits: Aged / Female / Humans / Male Country/Region as subject: Europa Language: English Journal: J Am Geriatr Soc Year: 2021 Document Type: Article Affiliation country: Jgs.17357

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Main subject: Pneumonia, Viral / Purines / Pyrazoles / Sulfonamides / Azetidines / COVID-19 / COVID-19 Drug Treatment Type of study: Cohort study / Diagnostic study / Experimental Studies / Observational study / Prognostic study / Randomized controlled trials Limits: Aged / Female / Humans / Male Country/Region as subject: Europa Language: English Journal: J Am Geriatr Soc Year: 2021 Document Type: Article Affiliation country: Jgs.17357